恒瑞医药(01276.HK)：注射用瑞康曲妥珠单抗获临床试验批准

Core Viewpoint - Heng Rui Medicine (01276.HK) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of injection Rituximab, which will commence soon [1] Group 1: Product Development - The injection Rituximab is set to be launched in China by May 2025 [1] - It is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic therapy [1]